Will FDA now stop conducting GMP inspections?
Recommendation
10/11 February 2026
Heidelberg, Germany
Medicinal Products/Drugs meet Medical Devices
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The European Medicines Agency, EMA, has updated its Q&A section on the Mutual Recognition Agreement. The questions mainly refer to the start of the operating phase of the agreement on 01 November 2017.
An important question is whether from 1 November 2017 FDA will stop conducting GMP inspections in all the EU Member States. It is pointed out that "it is expected" that FDA will not perform inspections in an EU Member State when the respective competent authorities have already been recognized by FDA. Currently these are Austria, Croatia, France, Italy, Malta, Spain, Sweden and United Kingdom. That means that FDA can and will still perform inspections in the states not recognized yet.
In this context, two more questions and answers complement the information:
"The number of recognized authorities will be gradually expanded with further assessment. The MRA foresees that all EU Member States are assessed by latest 15 July 2019." And that "the EU is publishing the list of recognized authorities" which will be regularly updated.
Related GMP News
04.02.2026When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
27.01.2026New Ph. Eur. Publication Schedule
21.01.2026EU Pharma Package: EMA with single Point of Information
14.01.2026European QP Association Developments September through December 2025
14.01.2026Could a change of ownership be relevant to GMP?
07.01.2026Is QP Certification required when Products do not enter EU Territory?